{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,24]],"date-time":"2026-03-24T14:11:13Z","timestamp":1774361473325,"version":"3.50.1"},"reference-count":46,"publisher":"Japan Atherosclerosis Society","issue":"6","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["JAT","J Atheroscler Thromb"],"published-print":{"date-parts":[[2024,6,1]]},"DOI":"10.5551\/jat.64502","type":"journal-article","created":{"date-parts":[[2023,12,13]],"date-time":"2023-12-13T22:13:24Z","timestamp":1702505604000},"page":"904-916","source":"Crossref","is-referenced-by-count":4,"title":["Cilostazol plus Aspirin vs. Clopidogrel plus Aspirin in Acute Minor Stroke or Transient Ischemic Attack"],"prefix":"10.5551","volume":"31","author":[{"given":"Hsin-Yi","family":"Huang","sequence":"first","affiliation":[{"name":"Department of Pharmacy, Shuang Ho Hospital, Taipei Medical University"},{"name":"School of Pharmacy, National Taiwan University"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jia-Hung","family":"Chen","sequence":"additional","affiliation":[{"name":"Department of Neurology, Shuang Ho Hospital, Taipei Medical University"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Nai-Fang","family":"Chi","sequence":"additional","affiliation":[{"name":"Department of Neurology, Taipei Veterans General Hospital"},{"name":"Department of Neurology, School of Medicine, National Yang Ming Chiao Tung University"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"You-Chia","family":"Chen","sequence":"additional","affiliation":[{"name":"Department of Neurology, Cathay General Hospital"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"3489","reference":[{"key":"1","doi-asserted-by":"crossref","unstructured":"1) Coull AJ, Lovett JK, Rothwell PM. Population based study of early risk of stroke after transient ischaemic attack or minor stroke: implications for public education and organisation of services. Bmj, 2004; 328: 326","DOI":"10.1136\/bmj.37991.635266.44"},{"key":"2","doi-asserted-by":"crossref","unstructured":"2) Lovett JK, Coull AJ, Rothwell PM. Early risk of recurrence by subtype of ischemic stroke in population-based incidence studies. Neurology, 2004; 62: 569-573","DOI":"10.1212\/01.WNL.0000110311.09970.83"},{"key":"3","doi-asserted-by":"crossref","unstructured":"3) Hill MD, Yiannakoulias N, Jeerakathil T, Tu JV, Svenson LW, Schopflocher DP. The high risk of stroke immediately after transient ischemic attack: a population-based study. Neurology, 2004; 62: 2015-2020","DOI":"10.1212\/01.WNL.0000129482.70315.2F"},{"key":"4","doi-asserted-by":"crossref","unstructured":"4) Powers WJ, Rabinstein AA, Ackerson T, Adeoye OM, Bambakidis NC, Becker K, Biller J, Brown M, Demaerschalk BM, Hoh B, Jauch EC, Kidwell CS, Leslie-Mazwi TM, Ovbiagele B, Scott PA, Sheth KN, Southerland AM, Summers DV, Tirschwell DL. 2018 Guidelines for the Early Management of Patients With Acute Ischemic Stroke: A Guideline for Healthcare Professionals From the American Heart Association\/American Stroke Association. Stroke, 2018; 49: e46-e110","DOI":"10.1161\/STR.0000000000000158"},{"key":"5","doi-asserted-by":"crossref","unstructured":"5) Johnston SC, Easton JD, Farrant M, Barsan W, Conwit RA, Elm JJ, Kim AS, Lindblad AS, Palesch YY. Clopidogrel and Aspirin in Acute Ischemic Stroke and High-Risk TIA. N Engl J Med, 2018; 379: 215-225","DOI":"10.1056\/NEJMoa1800410"},{"key":"6","doi-asserted-by":"crossref","unstructured":"6) Wang Y, Wang Y, Zhao X, Liu L, Wang D, Wang C, Wang C, Li H, Meng X, Cui L, Jia J, Dong Q, Xu A, Zeng J, Li Y, Wang Z, Xia H, Johnston SC. Clopidogrel with aspirin in acute minor stroke or transient ischemic attack. N Engl J Med, 2013; 369: 11-19","DOI":"10.1056\/NEJMoa1215340"},{"key":"7","doi-asserted-by":"crossref","unstructured":"7) Wang Y, Zhao X, Lin J, Li H, Johnston SC, Lin Y, Pan Y, Liu L, Wang D, Wang C, Meng X, Xu J, Wang Y. Association Between CYP2C19 Loss-of-Function Allele Status and Efficacy of Clopidogrel for Risk Reduction Among Patients With Minor Stroke or Transient Ischemic Attack. JAMA, 2016; 316: 70-78","DOI":"10.1001\/jama.2016.8662"},{"key":"8","doi-asserted-by":"crossref","unstructured":"8) Zhuo ZL, Xian HP, Long Y, Liu C, Sun YY, Ma YT, Gao H, Zhao JZ, Zhao XT. Association between CYP2C19 and ABCB1 polymorphisms and clopidogrel resistance in clopidogrel-treated Chinese patients. Anatol J Cardiol, 2018; 19: 123-129","DOI":"10.14744\/AnatolJCardiol.2017.8097"},{"key":"9","doi-asserted-by":"crossref","unstructured":"9) Zhong Z, Hou J, Zhang Q, Li B, Li C, Liu Z, Yang M, Zhong W, He X, Wu H, Zhong M, Zhao P. Effect of cytochrome P450 2C19 polymorphism on adverse cardiovascular events after drug-eluting stent implantation in a large Hakka population with acute coronary syndrome receiving clopidogrel in southern China. Eur J Clin Pharmacol, 2018; 74: 423-431","DOI":"10.1007\/s00228-017-2393-1"},{"key":"10","doi-asserted-by":"crossref","unstructured":"10) Su Q, Li J, Tang Z, Yang S, Xing G, Liu T, Peng H. Association of CYP2C19 Polymorphism with Clopidogrel Resistance in Patients with Acute Coronary Syndrome in China. Med Sci Monit, 2019; 25: 7138-7148","DOI":"10.12659\/MSM.915971"},{"key":"11","doi-asserted-by":"crossref","unstructured":"11) Sudo T, Tachibana K, Toga K, Tochizawa S, Inoue Y, Kimura Y, Hidaka H. Potent effects of novel anti-platelet aggregatory cilostamide analogues on recombinant cyclic nucleotide phosphodiesterase isozyme activity. Biochem Pharmacol, 2000; 59: 347-356","DOI":"10.1016\/S0006-2952(99)00346-9"},{"key":"12","doi-asserted-by":"crossref","unstructured":"12) Shinohara Y, Katayama Y, Uchiyama S, Yamaguchi T, Handa S, Matsuoka K, Ohashi Y, Tanahashi N, Yamamoto H, Genka C, Kitagawa Y, Kusuoka H, Nishimaru K, Tsushima M, Koretsune Y, Sawada T, Hamada C. Cilostazol for prevention of secondary stroke (CSPS 2): an aspirin-controlled, double-blind, randomised non-inferiority trial. Lancet Neurol, 2010; 9: 959-968","DOI":"10.1016\/S1474-4422(10)70198-8"},{"key":"13","doi-asserted-by":"crossref","unstructured":"13) Toyoda K, Uchiyama S, Yamaguchi T, Easton JD, Kimura K, Hoshino H, Sakai N, Okada Y, Tanaka K, Origasa H, Naritomi H, Houkin K, Yamaguchi K, Isobe M, Minematsu K, Investigators CScT. Dual antiplatelet therapy using cilostazol for secondary prevention in patients with high-risk ischaemic stroke in Japan: a multicentre, open-label, randomised controlled trial. Lancet Neurol, 2019; 18: 539-548","DOI":"10.1016\/S1474-4422(19)30148-6"},{"key":"14","unstructured":"14) Tajima H, Izumi T, Miyachi S, Matsubara N, Ito M, Imai T, Nishihori M, Shintai K, Okamoto S, Araki Y, Kumakura Y, Furukawa-Hibi Y, Yamada K, Wakabayashi T. Association between CYP2C19 genotype and the additional effect of cilostazol to clopidogrel resistance in neuroendovascular therapy. Nagoya J Med Sci, 2018; 80: 207-215"},{"key":"15","doi-asserted-by":"crossref","unstructured":"15) Kwon SU, Hong K-S, Kang D-W, Park J-M, Lee J-H, Cho Y-J, Yu K-H, Koo J-S, Wong KSL, Lee S-H, Lee KB, Kim D-E, Jeong S-W, Bae H-J, Lee B-C, Han M-K, Rha J-H, Kim HY, Mok VC, Lee Y-S, Kim G-M, Suwanwela NC, Yun S-C, Nah H-W, Kim JS. Efficacy and safety of combination antiplatelet therapies in patients with symptomatic intracranial atherosclerotic stenosis. Stroke, 2011; 42: 2883-2890","DOI":"10.1161\/STROKEAHA.110.609370"},{"key":"16","unstructured":"16) Health and Welfare Data Science Center, Ministry of Health and Welfare (HWDC, MOHW), https: \/\/dep.mohw.gov.tw\/DOS\/lp-3142-113.html"},{"key":"17","doi-asserted-by":"crossref","unstructured":"17) Lund JL, Richardson DB, St\u00fcrmer T. The active comparator, new user study design in pharmacoepidemiology: historical foundations and contemporary application. Curr Epidemiol Rep, 2015; 2: 221-228","DOI":"10.1007\/s40471-015-0053-5"},{"key":"18","doi-asserted-by":"crossref","unstructured":"18) Sung SF, Hsieh CY, Lin HJ, Chen YW, Chen CH, Kao Yang YH, Hu YH. Validity of a stroke severity index for administrative claims data research: a retrospective cohort study. BMC Health Serv Res, 2016; 16: 509","DOI":"10.1186\/s12913-016-1769-8"},{"key":"19","doi-asserted-by":"crossref","unstructured":"19) Sung SF, Hsieh CY, Kao Yang YH, Lin HJ, Chen CH, Chen YW, Hu YH. Developing a stroke severity index based on administrative data was feasible using data mining techniques. J Clin Epidemiol, 2015; 68: 1292-1300","DOI":"10.1016\/j.jclinepi.2015.01.009"},{"key":"20","doi-asserted-by":"crossref","unstructured":"20) Chen PL, Chen YJ, Chung CP, Seak CJ, Jeng JS, Hsieh MJ, Lien LM, Chen JH, Chen YW, Chiu TF, Lee JT, Ng CJ. Dual Antiplatelet Therapy in the Management of Acute Minor Ischemic Stroke and High-Risk Transient Ischemic Attack: An Expert Consensus Statement From Taiwan Stroke Society and Taiwan Society of Emergency Medicine. J Acute Med, 2022; 12: 85-95","DOI":"10.4103\/2221-6189.342666"},{"key":"21","unstructured":"21) Schainfeld RM. Management of peripheral arterial disease and intermittent claudication. J Am Board Fam Pract, 2001; 14: 443-450"},{"key":"22","doi-asserted-by":"crossref","unstructured":"22) Cosentino N, Campodonico J, Milazzo V, Celentano K, Moltrasio M, Faggiano P, Marenzi G. Extended dual antiplatelet therapy after acute myocardial infarction. Current evidence and future perspectives. Monaldi Arch Chest Dis, 2019; 89","DOI":"10.4081\/monaldi.2019.1046"},{"key":"23","doi-asserted-by":"crossref","unstructured":"23) Park Y, Franchi F, Rollini F, Angiolillo DJ. Dual antiplatelet therapy after coronary stenting. Expert Opin Pharmacother, 2016; 17: 1775-1787","DOI":"10.1080\/14656566.2016.1202924"},{"key":"24","unstructured":"24) Giacoppo D, Baber U, Mehran R. Current developments in dual antiplatelet therapy after stenting. Minerva Cardioangiol, 2014; 62: 261-276"},{"key":"25","doi-asserted-by":"crossref","unstructured":"25) Sung SF, Hsieh CY, Lin HJ, Chen YW, Yang YH, Li CY. Validation of algorithms to identify stroke risk factors in patients with acute ischemic stroke, transient ischemic attack, or intracerebral hemorrhage in an administrative claims database. Int J Cardiol, 2016; 215: 277-282","DOI":"10.1016\/j.ijcard.2016.04.069"},{"key":"26","doi-asserted-by":"crossref","unstructured":"26) Okere AN, Renier CM, Frye A. Predictors of Hospital Length of Stay and Readmissions in Ischemic Stroke Patients and the Impact of Inpatient Medication Management. J Stroke Cerebrovasc Dis, 2016; 25: 1939-1951","DOI":"10.1016\/j.jstrokecerebrovasdis.2016.04.011"},{"key":"27","doi-asserted-by":"crossref","unstructured":"27) Adams HP, Jr. Cancer and Cerebrovascular Disease. Curr Neurol Neurosci Rep, 2019; 19: 73","DOI":"10.1007\/s11910-019-0985-0"},{"key":"28","doi-asserted-by":"crossref","unstructured":"28) Hilkens NA, Algra A, Greving JP. Prediction models for intracranial hemorrhage or major bleeding in patients on antiplatelet therapy: a systematic review and external validation study. J Thromb Haemost, 2016; 14: 167-174","DOI":"10.1111\/jth.13196"},{"key":"29","doi-asserted-by":"crossref","unstructured":"29) Findlay MD, Thomson PC, Fulton RL, Solbu MD, Jardine AG, Patel RK, Stevens KK, Geddes CC, Dawson J, Mark PB. Risk Factors of Ischemic Stroke and Subsequent Outcome in Patients Receiving Hemodialysis. Stroke, 2015; 46: 2477-2481","DOI":"10.1161\/STROKEAHA.115.009095"},{"key":"30","doi-asserted-by":"crossref","unstructured":"30) Appelros P. Prediction of length of stay for stroke patients. Acta Neurol Scand, 2007; 116: 15-19","DOI":"10.1111\/j.1600-0404.2006.00756.x"},{"key":"31","doi-asserted-by":"crossref","unstructured":"31) Austin PC, Stuart EA. Moving towards best practice when using inverse probability of treatment weighting (IPTW) using the propensity score to estimate causal treatment effects in observational studies. Stat Med, 2015; 34: 3661-3679","DOI":"10.1002\/sim.6607"},{"key":"32","doi-asserted-by":"crossref","unstructured":"32) Ali MS, Groenwold RH, Pestman WR, Belitser SV, Roes KC, Hoes AW, de Boer A, Klungel OH. Propensity score balance measures in pharmacoepidemiology: a simulation study. Pharmacoepidemiol Drug Saf, 2014; 23: 802-811","DOI":"10.1002\/pds.3574"},{"key":"33","doi-asserted-by":"crossref","unstructured":"33) Zhang Z, Kim HJ, Lonjon G, Zhu Y. Balance diagnostics after propensity score matching. Ann Transl Med, 2019; 7: 16","DOI":"10.21037\/atm.2018.12.10"},{"key":"34","doi-asserted-by":"crossref","unstructured":"34) Archontakis-Barakakis P, Li W, Kalaitzoglou D, Tzelves L, Manolopoulos A, Giannopoulos S, Giamouzis G, Giannakoulas G, Batsidis A, Palaiodimos L, Ntaios G, Lip GYH, Kokkinidis DG. Effectiveness and safety of intracranial events associated with the use of direct oral anticoagulants for atrial fibrillation: A systematic review and meta-analysis of 92 studies. Br J Clin Pharmacol, 2022; 88: 4663-4675","DOI":"10.1111\/bcp.15464"},{"key":"35","doi-asserted-by":"crossref","unstructured":"35) Jung SJ, Shim SR, Kim BJ, Jung JM. Cilostazol-based dual anti-platelet agents for Asian patients: An updated network meta-analysis. J Neurol Sci, 2022; 442: 120457","DOI":"10.1016\/j.jns.2022.120457"},{"key":"36","doi-asserted-by":"crossref","unstructured":"36) Lee TH, Lin YS, Liou CW, Lee JD, Peng TI, Liu CH. Comparison of long-term efficacy and safety between cilostazol and clopidogrel in chronic ischemic stroke: a nationwide cohort study. Ther Adv Chronic Dis, 2020; 11: 2040622320936418","DOI":"10.1177\/2040622320936418"},{"key":"37","doi-asserted-by":"crossref","unstructured":"37) Diener HC, Bogousslavsky J, Brass LM, Cimminiello C, Csiba L, Kaste M, Leys D, Matias-Guiu J, Rupprecht HJ. Aspirin and clopidogrel compared with clopidogrel alone after recent ischaemic stroke or transient ischaemic attack in high-risk patients (MATCH): randomised, double-blind, placebo-controlled trial. Lancet, 2004; 364: 331-337","DOI":"10.1016\/S0140-6736(04)16721-4"},{"key":"38","doi-asserted-by":"crossref","unstructured":"38) Berger PB, Bhatt DL, Fuster V, Steg PG, Fox KA, Shao M, Brennan DM, Hacke W, Montalescot G, Steinhubl SR, Topol EJ. Bleeding complications with dual antiplatelet therapy among patients with stable vascular disease or risk factors for vascular disease: results from the Clopidogrel for High Atherothrombotic Risk and Ischemic Stabilization, Management, and Avoidance (CHARISMA) trial. Circulation, 2010; 121: 2575-2583","DOI":"10.1161\/CIRCULATIONAHA.109.895342"},{"key":"39","doi-asserted-by":"crossref","unstructured":"39) Klein MD, Williams AK, Lee CR, Stouffer GA. Clinical Utility of CYP2C19 Genotyping to Guide Antiplatelet Therapy in Patients With an Acute Coronary Syndrome or Undergoing Percutaneous Coronary Intervention. Arterioscler Thromb Vasc Biol, 2019; 39: 647-652","DOI":"10.1161\/ATVBAHA.118.311963"},{"key":"40","doi-asserted-by":"crossref","unstructured":"40) Yoshida K, Solomon DH, Kim SC. Active-comparator design and new-user design in observational studies. Nat Rev Rheumatol, 2015; 11: 437-441","DOI":"10.1038\/nrrheum.2015.30"},{"key":"41","doi-asserted-by":"crossref","unstructured":"41) Hoshino T, Uchiyama S, Wong LKS, Kitagawa K, Charles H, Labreuche J, Lavall\u00e9e PC, Albers GW, Caplan LR, Donnan GA, Ferro JM, Hennerici MG, Molina C, Rothwell PM, Steg PG, Touboul PJ, Vicaut \u00c9, Amarenco P. Five-Year Prognosis After TIA or Minor Ischemic Stroke in Asian and Non-Asian Populations. Neurology, 2021; 96: e54-e66","DOI":"10.1212\/WNL.0000000000010995"},{"key":"42","doi-asserted-by":"crossref","unstructured":"42) Hoshino T, Sissani L, Labreuche J, Bousser MG, Chamorro A, Fisher M, Ford I, Fox KM, Hennerici MG, Mattle HP, Rothwell PM, Gabriel Steg P, Vicaut E, Amarenco P. Non-cardioembolic stroke\/transient ischaemic attack in Asians and non-Asians: A post-hoc analysis of the PERFORM study. Eur Stroke J, 2019; 4: 65-74","DOI":"10.1177\/2396987318797245"},{"key":"43","doi-asserted-by":"crossref","unstructured":"43) Hsieh CY, Lee CH, Sung SF. Stroke occurrence while on antiplatelet therapy may predict atrial fibrillation detected after stroke. Atherosclerosis, 2019; 283: 13-18","DOI":"10.1016\/j.atherosclerosis.2019.01.007"},{"key":"44","doi-asserted-by":"crossref","unstructured":"44) Lin HL, Tsai CF, Liu SP, Muo CH, Chen PC. Association between aphasia and risk of dementia after stroke. J Stroke Cerebrovasc Dis, 2022; 31: 106838","DOI":"10.1016\/j.jstrokecerebrovasdis.2022.106838"},{"key":"45","doi-asserted-by":"crossref","unstructured":"45) Huang HY, Lin SY, Katz AJ, Sheu JJ, Lin FJ, Wang CC, Wu CH. Effectiveness and Safety of Clopidogrel vs Aspirin in Elderly Patients With Ischemic Stroke. Mayo Clin Proc, 2022; 97: 1483-1492","DOI":"10.1016\/j.mayocp.2022.01.033"},{"key":"46","doi-asserted-by":"crossref","unstructured":"46) Wang HP, Sung SF, Yang HY, Huang WT, Hsieh CY. Associations between stroke type, stroke severity, and pre-stroke osteoporosis with the risk of post-stroke fracture: A nationwide population-based study. J Neurol Sci, 2021; 427: 117512","DOI":"10.1016\/j.jns.2021.117512"}],"container-title":["Journal of Atherosclerosis and Thrombosis"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.jstage.jst.go.jp\/article\/jat\/31\/6\/31_64502\/_pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,6,1]],"date-time":"2024-06-01T04:41:56Z","timestamp":1717216916000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.jstage.jst.go.jp\/article\/jat\/31\/6\/31_64502\/_article"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,6,1]]},"references-count":46,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2024]]}},"URL":"https:\/\/doi.org\/10.5551\/jat.64502","relation":{},"ISSN":["1340-3478","1880-3873"],"issn-type":[{"value":"1340-3478","type":"print"},{"value":"1880-3873","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,6,1]]},"article-number":"64502"}}